MediWound (MDWD) Company presentation summary

Platform and portfolio

• Proprietary platform uses pineapple-stem raw material and topical proteolytic enzymes to selectively remove non-viable tissue without surgery.

• Portfolio spans marketed NexoBrid for burn eschar removal and investigational EscharEx for chronic-wound debridement and wound-closure support.

• Platform highlights include 14 successful clinical trials, 150+ peer-reviewed publications and FDA, EMA and Japan approvals.

NexoBrid

• Approved in 40+ countries, with 18,000+ patients treated; 2025 revenue was $17M and the product was described as profitable.

• Phase 3 data showed surgical eschar removal in 4% vs. 72% with SOC and blood loss of 14 mL vs. 815 mL; both comparisons had p<0.0001.

• Bedside topical application removes eschar within 4 hours and is described as preserving viable tissue, reducing surgery and reducing blood loss.

• Commercial availability: U.S. through Vericel, Japan through Kaken, and EU through direct sales and PMI.

EscharEx

• Investigational enzymatic therapy targets chronic wounds; VLU Phase 3 is ongoing, DFU trial preparation is underway, and a PU investigator-initiated trial is planned.

• Phase 2 ChronEx results: complete debridement within 2 weeks in 63% vs. 30% with placebo; median time to wound-bed preparation was 11 vs. 85 days.

• In Phase 2 PharmEx, 70% achieved complete debridement within 8 applications; bioburden fell 64% and wound size fell 35%.

• The VALUE Phase 3 study plans 216 VLU patients; interim sample-size assessment follows completion of the 12-week wound-management period by 65% of patients.

• U.S. TAM is presented as $4B, with projected peak sales of $1.05B based on an estimated 20.8% conversion across current debridement techniques.